Asthma is a chronic respiratory condition characterized by inflammation and narrowing of the airways, leading to symptoms such as wheezing ...

According to a real-world study, tezepelumab is an effective add-on biologic with a rapid onset of action for patients with both T2-high and T2-low severe asthma. The study was published ...

Among patients with severe asthma receiving dupilumab for 12 months, 91% had a clinical response and 30% achieved clinical remission.

Relevant biomarkers include cytokines and targets such as IL-4, IgE, IL-5, IL-13, IL-33, and TSLP (Figure 2). A number of ...

The latest UK asthma guidelines1 clearly define the role of Fractional exhaled Nitric Oxide (FeNO) testing in both diagnosing ...

Western researchers recently attracted $15M in CIHR project grants, created “to support the bold ideas and innovative work of Canada’s health researchers.” ...

Research exploring novel therapies to fight against bladder cancer and a world-first asthma study are among 18 Western projects drawing more than $15 ...

Children treated with mepolizumab during asthma flare-ups showed a significant reduction in eosinophil-driven type 2 (T2) ...

Scientists uncover shared genetic signals between chronic dry cough and ACE inhibitor-induced cough, pointing to neurological ...

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ('Kelun-Biotech' or 'the Company', HKEX: 6990) today announced that its partner, Windward Bio AG ('Windward Bio') has launched its Phase 2 POLARIS ...

Phase 2 POLARIS trial will evaluate the dosing, safety, and efficacy of HBM9378/WIN378 in patients with asthma, with an initial data readout expected in mid-2026 HBM9378/WIN378 has the potential to be ...

Roche’s hopes of getting its chronic obstructive pulmonary disease (COPD) drug astegolimab to regulators this year have taken ...